

1653

#13  
JP

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lawrence B. Sandberg et al.

Serial No.: 09/580,893

Art Unit: 1653

Filed: May 30, 2000

Title: ASPARAGINE CONTAINING ELASTIN PEPTIDE ANALOGS

Docket No.: 25812-14

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED

JUL 23 2003

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8

I hereby certify that the below-identified papers are being deposited with the United States Postal Service with sufficient postage as "FIRST CLASS MAIL" on July 18, 2003, in an envelope addressed to: Mail Stop DD, Commissioner for Patents, Alexandria, VA 22313-1450.

Dawn E. Snyder


(type or print name of person mailing paper)

Dawn E. Snyder

Signature of person mailing paper

Items enclosed herewith:

1. Information Disclosure Statement (two pages, in duplicate);
2. Form PTO-1449 (4 pages), with copy of references; and
3. Return receipt postcard.



ECEIVED

JUL 23 2003

TECH CENTER 1600/2900 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lawrence B. Sandberg et al.  
Serial No.: 09/580,893 Art Unit: 1653  
Filed: May 30, 2000  
Title: ASPARAGINE CONTAINING ELASTIN PEPTIDE ANALOGS  
Docket No.: 25812-14

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

1. This Information Disclosure Statement is filed in accordance with 36 C.F.R. §§ 1.56, 1.97 and 1.98. The items listed on the enclosed Form PTO-1449 may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.
2. Pursuant to 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.
3. Pursuant to 37 C.F.R. § 1.97(h), the filing of this Information Disclosure Statement shall not be construed as an admission that the information cited in this Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

4. Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed:

( ) within 3 months of the filing date of a national application; or

( ) within 3 months of the date of the entry of the national stage as set forth in 37 CFR 1.491 in an international application; or


(X) before the mailing date of a first Office Action on the merits.

It is believed that statements filed within the foregoing periods require neither a fee nor a certification.

The Commissioner is hereby authorized to charge any additional fees required for consideration of this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 02-2051, identifying our Docket No. 25812-14.

Respectfully Submitted,

Dated: 7/18/13

By:   
N. Nicole Endejann  
Registration No. 50,229

BENESCH, FRIEDLANDER,  
COPLAN & ARONOFF, LLP  
2300 BP Tower  
200 Public Square  
Cleveland, Ohio 44114  
(216) 363-4453